Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -66.43M | -75.88M | -69.43M | -65.23M | -61.07M |
| Total Depreciation and Amortization | 2.85M | 3.16M | 3.74M | 3.20M | 2.60M |
| Total Amortization of Deferred Charges | 3.00M | 3.20M | 3.20M | 3.20M | 3.20M |
| Total Other Non-Cash Items | 12.96M | 27.51M | 26.84M | 25.63M | 23.73M |
| Change in Net Operating Assets | -359.00K | 11.36M | -2.48M | 1.18M | 2.60M |
| Cash from Operations | -47.98M | -30.65M | -38.12M | -32.02M | -28.94M |
| Capital Expenditure | -37.00K | -315.00K | -429.00K | -589.00K | -892.00K |
| Sale of Property, Plant, and Equipment | 453.00K | 451.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 416.00K | 136.00K | -429.00K | -589.00K | -892.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.00K | 839.00K | 1.30M | 1.66M | 2.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.00K | 839.00K | 1.30M | 1.66M | 2.16M |
| Foreign Exchange rate Adjustments | 7.01M | -752.00K | 7.26M | 1.56M | -2.02M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.55M | -30.43M | -29.99M | -29.39M | -29.69M |